hotspot -WSS

hotspot

author：leisure time 2025-08-23 08:53:00 - browse：43653

After a drawn-out lobbying fight, ARPA-H chose its headquarters: a hub and spokes model, with three central locations in Boston, Texas, and D.C. David L. Ryan/Boston Globe

WASHINGTON — Cities and states have been clamoring to play host to the Advanced Research Projects Agency for Health since before the agency existed — before, in fact, anyone truly knew what ARPA-H was.

But the lobbying campaign from universities, business leaders, members of Congress, and big-city mayors is finally over.

The end came not with a dramatic reveal or a formal ribbon-cutting, but with a largely bureaucratic and anticlimactic announcement that the Biden administration plans to share the wealth. ARPA-H will be housed in a hub-and-spoke model across three major metro areas: The D.C. suburbs; Cambridge, Mass.; and Dallas. Additional “spokes,” the agency announced Tuesday, will be spread across the country at 10 sites spanning from Florida to Alaska.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： How I helped Pfizer think through the ethics of Viagra

knowledge

WSS

Late stage cancers on the rise after pandemic delayed screenings

Heart disease in astronauts blamed on cosmic radiation

How to ethically and practically extend health care to all

Personalized medicine goes far beyond genetics

CommonSpirit Health keeps growing, even as it loses money

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

knowledge

hotspot

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Alnylam reports growth in sales of rare disease treatments

Virginia high school admissions case could be legal follow

Biotech lab space demand falls sharply

Heart attack and stroke risk calculators need revising

Hearing on Medicare drug price negotiation gets unusually heated

Moonlake's readout produced a cash windfall. Risks remain

Changes to biosimilar regulatory framework must prioritize patients

Trump demands the U.S. pay no more for drugs than other countries … again

How AI helped researchers track recovery from depression

hotspot

The cancer stories no one wants to hear

CommonSpirit Health keeps growing, even as it loses money

Biotech stock slump in 2023: awaiting the turnaround

Medicare slashes safety net hospital payments by nearly $1 billion

FDA panel to weigh approval of NurOwn, controversial ALS drug

Chris Christie meets with Zelenskyy during Ukraine trip

leisure time

knowledge

hotspot

hotspot